Related Experiment Videos
Imipenem-antibiotic monotherapy in juvenile cancer patients with neutropenia
Insights
Imipenem monotherapy is more effective than conventional antibiotics for treating fever and neutropenia in pediatric cancer patients. This approach reduces fever duration, side effects, and costs, even after bone marrow transplantation.
Area of Science:
- Pediatric Oncology
- Infectious Diseases
- Pharmacology
Background:
- Fever and neutropenia are common complications in pediatric cancer patients.
- Conventional antibiotic combinations are standard treatment but can have limitations.
Purpose of the Study:
- To compare the efficacy of imipenem monotherapy versus conventional antibiotic combination therapy.
- To evaluate treatment outcomes in febrile neutropenic pediatric cancer patients.
Main Methods:
- Retrospective analysis of 90 febrile episodes in 45 pediatric cancer patients.
- Comparison of imipenem monotherapy against a standard antibiotic combination (penicillin/cephalosporin/aminoglycoside).
- Inclusion of patients in myeloaplastic phase post-bone marrow transplantation.
Main Results:
- Imipenem showed comparable or superior efficacy to combination therapy.
- Shorter duration of fever and treatment observed with imipenem.
- Lower incidence of side effects and reduced costs associated with imipenem monotherapy.
- Susceptibility of Coagulase-negative Staphylococci to imipenem.
Conclusions:
- Imipenem monotherapy is a highly efficacious alternative to conventional combination therapy for febrile neutropenia in pediatric cancer patients.
- Imipenem offers advantages including reduced treatment duration, side effects, and costs.
- This approach is effective even in the critical post-bone marrow transplantation period.
Abstract:
From 1984 to 1987 two consecutive groups of juvenile cancer patients (n = 45) with fever and neutropenia corresponding in all criteria were examined. In half of the total of 90 febrile episodes and septicemias, a conventional antibiotic combination therapy (Pseudomonas-active penicillin/cephalosporin of the third generation/aminoglycoside) was instituted. In the remaining half imipenem was used as an antibiotic monoagent. In 66% and 60% of the febrile episodes treated with antibiotic combination therapy and with imipenem, respectively, septicemia was confirmed by positive blood cultures. Nineteen febrile episodes occurred in the myeloaplastic phase after bone marrow transplantation. In a comparative study of imipenem as monotherapy versus an antibiotic combination therapy the results obtained with imipenem were superior in many regards. No resistance developed necessitating change of antibiotic therapy. Coagulase-negative Staphylococci, primarily responsible for catheter-associated septicemia, were susceptible. Duration of fever and thus duration of treatment were shorter. The incidence of side effects and costs were lower. Therefore, imipenem as an antibiotic monotherapy in febrile cancer patients with neutropenia appears to be more efficacious than the conventional combination therapy, even during myeloaplasia following bone marrow transplantation. The results and rationale of this retrospective analysis are discussed.